search
Back to results

How to Treat Opiate Withdrawal in Neonates

Primary Purpose

Neonatal Abstinence Syndrome

Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Phenobarbital
Chlorpromazine
Morphine
Sponsored by
University of Zurich
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Neonatal Abstinence Syndrome focused on measuring opiate dependence, withdrawal, newborn

Eligibility Criteria

1 Hour - 3 Days (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Neonates of mothers who consumed opiates during pregnancy
  • Born after 34 completed weeks of pregnancy
  • Parents' informed consent

Exclusion Criteria:

  • Preterm birth before 34 0/7 gestational weeks
  • Severe malformation
  • Illness requiring respiratory assistance or catecholamines
  • Negative meconium drug test

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Experimental

    Active Comparator

    Active Comparator

    Arm Label

    Phenobarbital

    Chlorpromazine

    Morphine

    Arm Description

    Phenobarbitone loading dose 10 mg/kg body weight maintenance dose 0.83 mg/kg body weight every 4 hours

    Chlorpromazine loading dose 0.5 mg/kg body weight maintenance dose 0.25 mg/kg every 4 hours

    Morphine (tinctura opii) 0.25 mg/kg body weight every 4 hours

    Outcomes

    Primary Outcome Measures

    Duration of treatment
    Treatment is reduced stepwise until withdrawal symptoms have gone

    Secondary Outcome Measures

    Incidence of convulsions
    Weight gain
    Treatment failures (need for adding second medication)
    Need for additional drug if investigational drug does not control withdrawal symptoms

    Full Information

    First Posted
    June 2, 2009
    Last Updated
    January 6, 2020
    Sponsor
    University of Zurich
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02810782
    Brief Title
    How to Treat Opiate Withdrawal in Neonates
    Official Title
    Pharmacological Treatment of Narcotic Neonatal Withdrawal
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    December 2019
    Overall Recruitment Status
    Completed
    Study Start Date
    June 2001 (undefined)
    Primary Completion Date
    December 2007 (Actual)
    Study Completion Date
    December 2007 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    University of Zurich

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Three different drugs are used in a randomised, double blind, clinical multi-centre trial with three arms. Major objective is to investigate the duration of drug treatment based on the Finnegan score. Secondary objectives are to document weight gain, the need for adding a second drug when the first drug is not effective enough and possible side effects such as convulsions.
    Detailed Description
    Background: Neonatal narcotic abstinence syndrome is an important medical, social and financial problem. Several drugs are used to treat the withdrawal symptoms in neonates that have been exposed to opiates in utero, but there is no consensus which one is best. Goal: Three different drugs are used in a randomised, double blind, clinical multi-centre trial with three arms. Major objective is to investigate the duration of drug treatment based on the Finnegan score. Secondary objectives are to document weight gain, the need for adding a second drug when the first drug is not effective enough and possible side effects such as convulsions. Methods: Neonates born after 34 completed weeks of gestation with meconium proven antenatal opiate exposure and parental informed consent are included. Infants with severe malformation are excluded. Each infant is assessed every eight hour by a modified Finnegan score. When 9 points are exceeded drug treatment is started and dose increased stepwise according to the score. The masqued solution applied orally contains morphine, phenobarbital or chlorpromazine. When the maximum dose does not reduce the score, a second randomisation and one of the two remaining drugs is added, again in a blinded way. A total of 120 infants, 40 in each group will be included in the study.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Neonatal Abstinence Syndrome
    Keywords
    opiate dependence, withdrawal, newborn

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    120 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Phenobarbital
    Arm Type
    Experimental
    Arm Description
    Phenobarbitone loading dose 10 mg/kg body weight maintenance dose 0.83 mg/kg body weight every 4 hours
    Arm Title
    Chlorpromazine
    Arm Type
    Active Comparator
    Arm Description
    Chlorpromazine loading dose 0.5 mg/kg body weight maintenance dose 0.25 mg/kg every 4 hours
    Arm Title
    Morphine
    Arm Type
    Active Comparator
    Arm Description
    Morphine (tinctura opii) 0.25 mg/kg body weight every 4 hours
    Intervention Type
    Drug
    Intervention Name(s)
    Phenobarbital
    Other Intervention Name(s)
    Phenobarbitone
    Intervention Description
    Phenobarbital per os
    Intervention Type
    Drug
    Intervention Name(s)
    Chlorpromazine
    Other Intervention Name(s)
    Largactil
    Intervention Description
    Chlorpromazine per os
    Intervention Type
    Drug
    Intervention Name(s)
    Morphine
    Other Intervention Name(s)
    tinctura opii
    Intervention Description
    Morphine per os
    Primary Outcome Measure Information:
    Title
    Duration of treatment
    Description
    Treatment is reduced stepwise until withdrawal symptoms have gone
    Time Frame
    0 to 42 days
    Secondary Outcome Measure Information:
    Title
    Incidence of convulsions
    Time Frame
    Whole time of hospitalisation (up to 10 weeks)
    Title
    Weight gain
    Time Frame
    through study completion, up to 10 weeks
    Title
    Treatment failures (need for adding second medication)
    Description
    Need for additional drug if investigational drug does not control withdrawal symptoms
    Time Frame
    through study completion, up to 10 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    1 Hour
    Maximum Age & Unit of Time
    3 Days
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Neonates of mothers who consumed opiates during pregnancy Born after 34 completed weeks of pregnancy Parents' informed consent Exclusion Criteria: Preterm birth before 34 0/7 gestational weeks Severe malformation Illness requiring respiratory assistance or catecholamines Negative meconium drug test
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Hans U Bucher, Prof
    Organizational Affiliation
    University of Zurich
    Official's Role
    Study Chair

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    31691849
    Citation
    Zimmermann U, Rudin C, Duo A, Held L, Bucher HU; Swiss neonatal abstinence syndrome study group. Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial. Eur J Pediatr. 2020 Jan;179(1):141-149. doi: 10.1007/s00431-019-03486-6. Epub 2019 Nov 6.
    Results Reference
    result

    Learn more about this trial

    How to Treat Opiate Withdrawal in Neonates

    We'll reach out to this number within 24 hrs